Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Fibrotic interstitial lung diseases, like idiopathic pulmonary fibrosis (IPF), commonly overlap with lung cancer—a key ...
UK Biobank data linked 7-day wrist light sensing to CMR 3.1 years later, contrasting >3 lux nighttime exposure with none.
Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD ...
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests escalating treatment in patients with chronic ...
Takeda’s oveporexton (Orzeyful), a selective OX2R agonist, is the first therapy targeting orexin deficiency in NT1, improving ...
In "Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD," the mental health experts examined ...
Francesca Puggioni, MD, explains how real-world registry data, like the EU-ADVANTAGE study, informs regulatory decisions on ...
VHA/CMS screening identified 11,809 veterans with PV; after exclusions, 5,287 and 5,245 were analyzed for mortality and ...
In "Inside the Be Well Trials: Design, Population, and Patient Selection," the panel walks through why the Be Well trials ...
In "Cross-Trial Vitiligo Data: What Payers Can and Can't Compare," the panel compares cross-trial data directly and discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results